HC Wainwright Reaffirms “Buy” Rating for Genmab A/S (NASDAQ:GMAB)

HC Wainwright restated their buy rating on shares of Genmab A/S (NASDAQ:GMAB) in a research note released on Monday, AnalystRatings.com reports. The firm currently has a $24.00 price objective on the stock.

“We use a discounted cash flow (DCF)-based approach to valuing 2.0% terminal growth rate, 8.0% discount rate and 23% effective tax rate. We assign a 90% probability of approval to DARZALEX in smoldering MM; a 95% probability to ARZERRA in relapsing-remitting multiple sclerosis (RR-MS); an 85% probability to teprotumumab; a 20% probability to enapotamab vedotin in 35% probabilities of approval to tisotumab vedotin for cervical cancer and ovarian cancer, respectively.”,” HC Wainwright’s analyst commented.

Several other research firms also recently weighed in on GMAB. Royal Bank of Canada began coverage on Genmab A/S in a research note on Monday, August 12th. They issued an outperform rating and a $23.00 price target for the company. JPMorgan Chase & Co. upgraded Genmab A/S from a neutral rating to an overweight rating and set a $23.00 price target for the company in a research note on Thursday, September 12th. Bank of America upgraded Genmab A/S from a neutral rating to a buy rating in a research note on Friday, September 13th. Morgan Stanley began coverage on Genmab A/S in a research note on Monday, August 12th. They issued an overweight rating for the company. Finally, Guggenheim began coverage on Genmab A/S in a research note on Monday, August 12th. They issued a buy rating for the company. Six analysts have rated the stock with a buy rating, The company has an average rating of Buy and an average target price of $23.33.

GMAB stock opened at $20.49 on Monday. Genmab A/S has a 1-year low of $12.10 and a 1-year high of $21.45. The business has a 50 day simple moving average of $19.86.

Genmab A/S (NASDAQ:GMAB) last posted its quarterly earnings results on Wednesday, August 14th. The company reported $0.20 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.07 by $0.13. The business had revenue of $116.49 million during the quarter. On average, equities analysts anticipate that Genmab A/S will post 0.41 earnings per share for the current fiscal year.

A hedge fund recently bought a new stake in Genmab A/S stock. Parametric Portfolio Associates LLC bought a new stake in shares of Genmab A/S (NASDAQ:GMAB) in the second quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor bought 375,476 shares of the company’s stock, valued at approximately $6,937,000. Parametric Portfolio Associates LLC owned about 0.29% of Genmab A/S as of its most recent filing with the Securities and Exchange Commission. Institutional investors own 0.83% of the company’s stock.

About Genmab A/S

Genmab A/S, a biotechnology company, develops antibody therapeutics for the treatment of cancer primarily in Denmark. The company markets DARZALEX, a human IgG1k monoclonal antibody for the treatment of patients with multiple myeloma (MM); and Arzerra, a human IgG1k monoclonal antibody for the treatment of chronic lymphocytic leukemia (CLL).

Featured Article: Stocks Increasing Dividends

Analyst Recommendations for Genmab A/S (NASDAQ:GMAB)

Receive News & Ratings for Genmab A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genmab A/S and related companies with MarketBeat.com's FREE daily email newsletter.